The Medicines and Healthcare products Regulatory Agency (MHRA) has initiated a recall of all quetiapine oral suspension batches from Eaststone Limited due to a manufacturing error resulting in twice the correct amount of active ingredient. Affected batches, produced between 26 October 2025 and 26 January 2026, are unlicensed ‘special’ medicines used for psychiatric conditions. Patients are advised not to stop treatment without consulting healthcare professionals and to check their medication for batch numbers. The MHRA warns of overdose risks, including extreme drowsiness and breathing difficulties, and urges immediate medical attention if symptoms occur. Healthcare providers must contact affected patients and review treatment options. Further details are available in the National Patient Safety Alert. The MHRA emphasizes patients should report adverse reactions via the Yellow Card scheme.
© Crown copyright, 2024, GOV.UK.
Summary adapted from content licensed under the Open Government Licence v3.0.
For details, see https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/.
Original source: https://www.gov.uk/
https://www.gov.uk/government/news/medicines-recall-of-all-quetiapine-oral-suspension-batches-from-eaststone-limited-due-to-incorrect-amount-of-active-ingredient
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.